The aim of research is to evaluate the work of vasoconstrictive and vasodilatative neurohormonal systems based on the copeptin’s and MRproADM’s definition in patients with acute myocardial infarction (AMI) and concomitant obesity with the complications and to analyse the prognostic properties of these markers on the development of acute heart failure (AHF).
Materials and methods. The study included 70 patients with AMI and concomitant obesity, whose average age was (66.64±1.31) years. Patients were divided into groups depending on the presence of complications of AMI — AHF (acute left ventricular failure). The first group included patients with AHF on the background of AMI with a concomitant obesity (n=38). The second group included patients with AMI and concomitant obesity without AHF (n=32).
Results and discussion. The presence of AMI complicated by AHF in patients with concomitant obesity associated with MRproADM’s high levels compared with patients without complications, indicating increased vasodilatory activity of neuroregulative system. Copeptin’s level did not differ significantly in the presence or absence of complications in patients with AMI and obesity, suggesting no significant differences in the studied groups of patients in the work of vasoconstrictional system. MRproADM in patients with AMI and obesity showed improved performance, which makes the possibility of its using as a marker of prognosis and severity of AHF in this cohort of patients.